Crawford Heads Into Q3 Print on a 13% August Rally
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
CRD.B enters its Q3 earnings release today having already told investors a great deal about the quarter. The August print delivered a 13.5% single-day gain, and the stock added another 15.9% over the following five days. That reaction set a high bar for any repeat performance.
The lending market is firmly in the background here. Short interest is negligible at 0.16% of free float, and availability is as loose as it gets. Borrowing costs have drifted higher over the past month, up roughly 26% from late September to 6.29%, but at that level they reflect normal small-cap borrow friction rather than any directional short thesis. There is no meaningful squeeze pressure and no speculative overhang.
The ownership structure is the more telling angle heading into today. Jesse Crawford holds roughly 46% of shares, a concentration that insulates the stock from institutional selling pressure but also limits liquidity. BlackRock added 162,774 shares in the quarter ended September 30, a quiet but deliberate build. Royce & Associates and First Wilshire both added material positions in the June quarter. Institutional conviction is accumulating, not retreating.
The debate about Crawford's value is effectively unanswered by the analyst community. The sole actionable target in the data, a Truist Securities Buy rating with an $11 target, was filed in August 2023 and is too stale to carry weight at a current price of $12.19. The stock has moved beyond it. With an EV/EBITDA of 4.7x and a PE near 7x, the multiples look undemanding, but the company operates in a claims-management niche where revenue is event-driven, tied to catastrophe activity and insurer outsourcing trends.
Today's print will test whether the August quarter's strong revenue and margin performance was a durable step-change in Crawford's earnings power, or a function of elevated claims activity that normalises into Q3.
Stocks in this article
See the live data behind this article on ORTEX.
Open CRD.B on ORTEX →How this article was generated
- Generated
- 3 Nov 2026, 05:24
- Data as of
- 3 Nov 2026, 04:21
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.